Streetbeat News

NRXS

NeurAxis, Inc.

https://neuraxis.com

Industry

Biotechnology

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Open

2.60

Mkt cap

18M

Volume

6.7K

High

2.60

P/E Ratio

-1.14

52-wk high

3.89

Low

2.40

Div yield

N/A

52-wk low

2.00

Neuraxis shares rose following the announcement of a new CPT category I code for percutaneous electrical nerve field stimulation, potentially enhancing the company's market position.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 4:28 pm

NeurAxis, Inc. (NYSE:NRXS) announced a new CPT Category I code for its PENFS technology, IB-Stim, effective January 1, 2026. This FDA-cleared device addresses functional abdominal pain in adolescents with IBS, offering a non-drug alternative.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 1:17 pm

NeurAxis announced that BlueCrossBlueShield Vermont will cover its PENFS treatment starting October 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 1:05 pm

Neuraxis shares are trading higher after the company reported a year-over-year increase in Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 4:38 pm

Neuraxis (AMEX:NRXS) reported Q2 EPS of $(0.42), a significant improvement from $(1.21) YoY, but sales decreased by 5.34% to $611.50K from $646.02K YoY.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 12:18 pm

NeurAxis has submitted an application to the FDA to expand the label for its IB-Stim device. Additionally, the company has provided compliance with NYSE guidelines.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 1:03 pm

Neuraxis (AMEX:NRXS) reported Q1 2024 GAAP EPS of $(0.32), a significant improvement from $(1.18) YoY. However, sales of $646.635K missed the $2.229M estimate by 70.99%, and decreased 19.68% YoY.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:10 pm

NeurAxis has announced the publication of a medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) with a Blue Cross Blue Shield license in Florida. This development could potentially expand the market for NeurAxis' medical devices.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 1:07 pm

NeurAxis, a biotechnology firm, has announced that its innovative medical treatments will now be covered under new medical policy in North Dakota. This expansion into North Dakota represents a significant step for NeurAxis in increasing the accessibility of its treatments.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 1:10 pm

Earnings reports for April 9, 2024, include a mix of projected losses and gains across various sectors. Tilray Brands, Cognyte Software, and Nauticus Robotics are expected to report losses, while Neogen, SMART Global Holdings, WD-40, and Pricesmart anticipate profits. Other companies like Neuraxis, Greenidge Generation, and Aehr Test Systems will also report their financial outcomes.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 9:35 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.